Monopar Therapeutics Inc.
MNPR
$60.63
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.50% | 47.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.11% | 50.38% | |||
| Operating Income | 15.11% | -50.38% | |||
| Income Before Tax | 25.14% | -51.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.14% | -51.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.14% | -51.29% | |||
| EBIT | 15.11% | -50.38% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 25.16% | -26.30% | |||
| Normalized Basic EPS | 25.15% | -26.29% | |||
| EPS Diluted | 25.16% | -26.30% | |||
| Normalized Diluted EPS | 25.15% | -26.29% | |||
| Average Basic Shares Outstanding | 0.02% | 19.79% | |||
| Average Diluted Shares Outstanding | 0.02% | 19.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||